Lauren P Wallner1,2,3, Mousumi Banerjee3,4, David Reyes-Gastelum1, Ann S Hamilton5, Kevin C Ward6, Carrie Lubitz7, Sarah T Hawley1,3,8, Megan R Haymart1,3. 1. University of Michigan, Department of Internal Medicine, Ann Arbor, MI, USA. 2. University of Michigan, Department of Epidemiology, Ann Arbor, MI, USA. 3. University of Michigan, Institute for Healthcare Policy and Innovation, Ann Arbor, MI, USA. 4. University of Michigan, Department of Biostatistics, Ann Arbor, MI, USA. 5. Keck School of Medicine, University of Southern California, Department of Preventive Medicine, Los Angeles, CA, USA. 6. Emory University, Department of Epidemiology, Atlanta, GA, USA. 7. Massachusetts General Hospital, Department of Surgery, Boston, MA, USA. 8. University of Michigan, Departments of Health Management and Policy and Health Behavior and Education, Ann Arbor, MI, USA.
Abstract
CONTEXT: The use of radioactive iodine (RAI) for low-risk thyroid cancer is common, and variation in its use exists, despite the lack of benefit for low-risk disease and potential harms and costs. OBJECTIVE: To simultaneously assess patient- and physician-level factors associated with patient-reported receipt of RAI for low-risk thyroid cancer. METHODS: This population-based survey study of patients with newly diagnosed differentiated thyroid cancer identified via the Surveillance Epidemiology and End Results (SEER) registries of Georgia and Los Angeles County included 989 patients with low-risk thyroid cancer, linked to 345 of their treating general surgeons, otolaryngologists, and endocrinologists. We assessed the association of physician- and patient-level factors with patient-reported receipt of RAI for low-risk thyroid cancer. RESULTS: Among this sample, 48% of patients reported receiving RAI, and 23% of their physicians reported they would use RAI for low-risk thyroid cancer. Patients were more likely to report receiving RAI if they were treated by a physician who reported they would use RAI for low-risk thyroid cancer compared with those whose physician reported they would not use RAI (adjusted OR: 1.84; 95% CI, 1.29-2.61). The odds of patients reporting they received RAI was 55% lower among patients whose physicians reported they saw a higher volume of patients with thyroid cancer (40+ vs 0-20) (adjusted OR: 0.45; 0.30-0.67). CONCLUSIONS: Physician perspectives and attitudes about using RAI, as well as patient volume, influence RAI use for low-risk thyroid cancer. Efforts to reduce overuse of RAI in low-risk thyroid cancer should include interventions targeted toward physicians, in addition to patients.
CONTEXT: The use of radioactive iodine (RAI) for low-risk thyroid cancer is common, and variation in its use exists, despite the lack of benefit for low-risk disease and potential harms and costs. OBJECTIVE: To simultaneously assess patient- and physician-level factors associated with patient-reported receipt of RAI for low-risk thyroid cancer. METHODS: This population-based survey study of patients with newly diagnosed differentiated thyroid cancer identified via the Surveillance Epidemiology and End Results (SEER) registries of Georgia and Los Angeles County included 989 patients with low-risk thyroid cancer, linked to 345 of their treating general surgeons, otolaryngologists, and endocrinologists. We assessed the association of physician- and patient-level factors with patient-reported receipt of RAI for low-risk thyroid cancer. RESULTS: Among this sample, 48% of patients reported receiving RAI, and 23% of their physicians reported they would use RAI for low-risk thyroid cancer. Patients were more likely to report receiving RAI if they were treated by a physician who reported they would use RAI for low-risk thyroid cancer compared with those whose physician reported they would not use RAI (adjusted OR: 1.84; 95% CI, 1.29-2.61). The odds of patients reporting they received RAI was 55% lower among patients whose physicians reported they saw a higher volume of patients with thyroid cancer (40+ vs 0-20) (adjusted OR: 0.45; 0.30-0.67). CONCLUSIONS: Physician perspectives and attitudes about using RAI, as well as patient volume, influence RAI use for low-risk thyroid cancer. Efforts to reduce overuse of RAI in low-risk thyroid cancer should include interventions targeted toward physicians, in addition to patients.
Authors: R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha Journal: Thyroid Date: 2010-10-29 Impact factor: 6.568
Authors: Maria Papaleontiou; David Reyes-Gastelum; Brittany L Gay; Kevin C Ward; Ann S Hamilton; Sarah T Hawley; Megan R Haymart Journal: Thyroid Date: 2019-07-25 Impact factor: 6.568
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Megan R Haymart; Mousumi Banerjee; Andrew K Stewart; Ronald J Koenig; John D Birkmeyer; Jennifer J Griggs Journal: JAMA Date: 2011-08-17 Impact factor: 56.272
Authors: Steven J Katz; Sarah T Hawley; Paul Abrahamse; Monica Morrow; Christopher R Friese; Amy K Alderman; Jennifer J Griggs; Ann S Hamilton; John J Graff; Timothy P Hofer Journal: Med Care Date: 2010-10 Impact factor: 2.983
Authors: Sarah T Hawley; Jennifer J Griggs; Ann S Hamilton; John J Graff; Nancy K Janz; Monica Morrow; Reshma Jagsi; Barbara Salem; Steven J Katz Journal: J Natl Cancer Inst Date: 2009-08-31 Impact factor: 13.506
Authors: Anna M Sawka; Sharon Straus; Gary Rodin; Lineke Heus; James D Brierley; Richard W Tsang; Lorne Rotstein; Shereen Ezzat; Phillip Segal; Amiram Gafni; Kevin E Thorpe; David P Goldstein Journal: Cancer Date: 2015-07-20 Impact factor: 6.860
Authors: Elisa Pasqual; Julie Ann Sosa; Yingxi Chen; Sara J Schonfeld; Amy Berrington de González; Cari M Kitahara Journal: Thyroid Date: 2022-03-15 Impact factor: 6.506